Clinical Study
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
Figure 1
Kaplan Meier 5-year survival for the ER/PR/HER2 subtypes for all stages combined (a), stage 1 (b), stage 2 (c), and stage 3 (d).